Enlivex, a cell immunotherapy company, is developing an autologous and allogeneic drug pipeline for the treatment of autoimmune and inflammatory conditions such as Graft versus Host Disease (GvHD), solid organ transplant rejection, and Crohn’s disease.

Our revolutionary approach to inducing immune tolerance utilizes apoptotic cells to activate the body's innate, physiologic mechanism for down-regulating inflammation and autoimmunity.